Jennifer King, MD, PhD
UCLA
Los Angeles, California, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Dana DiRenzo, MD, RhMSUS, MHS
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Disclosure(s): Amgen: Consultant (Ongoing); Novartis: Consultant (Ongoing)
Jennifer Grossman, MD
UCLA
Sherman Oaks, CA, United States
Disclosure(s): american board of internal medicine: Advisor or Review Panel Member (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); exact sciences: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); GlaxoSmithKlein(GSK): Grant/Research Support (Ongoing); ilumina: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); iqvia: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Lupus Foundation of America: Officer or Board Member (Ongoing); Merck/MSD: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); rheumatology research foundation: Grant/Research Support (Ongoing)
The intent of this session is to present the new Sjögren's peripheral neuropathy guidelines. The session with then highlight examples of Sjögren's neuropathy and the implementation of those guidelines.
Speaker: R. Hal Scofield, MD – Oklahoma Medical Research Foundation